Heart shield? common diabetes drug tested to prevent chemo damage in breast cancer

NCT ID NCT06427226

Recruiting now Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether dapagliflozin, a drug used for diabetes, can prevent heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. Researchers will enroll 46 women with early-stage breast cancer who are about to start chemotherapy. Participants will take dapagliflozin daily during their treatment cycles, and doctors will monitor heart function using echocardiograms and blood tests to see if the drug helps maintain a healthy heart.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a diabetes drug repurposed to protect the heart)
What this could lead to: If it works, this could offer a simple way to protect breast cancer patients' hearts during chemotherapy, reducing the risk of long-term heart problems.
What could go wrong: This is a small, early-phase trial with only 46 participants, so results may not apply to everyone. Dapagliflozin may not prevent heart damage, and side effects like dehydration or infection are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm doxorubicin induced cardiomyopathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER DOXORUBICIN INDUCED CARDIOMYOPATHY

Contacts and locations

Locations

Medical Research Institute
RECRUITING

Alexandria, Bab Sharqi, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.